Pomalidomide (CC-4047)

Catalog No.S1567

For research use only.

Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

Pomalidomide (CC-4047) Chemical Structure

CAS No. 19171-19-8

Selleck's Pomalidomide (CC-4047) has been cited by 89 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
Features A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
Targets
CRBN [5] TNF-α [1]
(PBMCs)
13 nM
In vitro

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NIW2V3VEgXSxdH;4bYNqfHliQYPzZZk> MWGxNEDPxE1? NV\pcZNVOjRiaB?= MoD3dI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GU MkHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|M{iyO|MoRjJ4M{O4Nlc{RC:jPh?=
J-CD38 NHHnZodEgXSxdH;4bYNqfHliQYPzZZk> Mni1NVAh|ryP M3PGXVI1KGh? NWDSOoQ5eG:2ZX70cJkh[XWpbXXueJMh\Gm{ZXP0JIFv\CCrbnTpdoVkfCCPTTDj[YxtKGurbHzpcoch[nliU1HS MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN|OEK3N{c,OjZ|M{iyO|M9N2F-
R-CD38 NVy0WVFVS3m2b4TvfIlkcXS7IFHzd4F6 MUWxNEDPxE1? M{fJPVI1KGh? NXO4N2J2eG:2ZX70cJkh[XWpbXXueJMh\Gm{ZXP0JIFv\CCrbnTpdoVkfCCPTTDj[YxtKGurbHzpcoch[nliU1HS M4juZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{O4Nlc{Lz5{NkOzPFI4OzxxYU6=
BC-3 M1LsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\UN|M6NTF{NUCgcm0> MU[1JIQ> NHrVPXFFVVORwrC= MVjJR|UxRTFyNzDuUUwhcW6qaXLpeJMh[2WubDDJR|UxRTFyNzDuUUwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NFr6V489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
BCBL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjCblc{QS1zMkWwJI5O NELRUJA2KGR? NH;keYZFVVORwrC= NXTOSmdlUUN3ME23OEBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NH30N3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
JSC-1 NWDnWJZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnXTYdKOzlvMUK1NEBvVQ>? NXHoWW45PSCm NWezS|JyTE2VT9Mg NFzKb|hKSzVyPUO0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MlWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
VG-1 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO5N|kuOTJ3MDDuUS=> MWO1JIQ> M2W0RWROW00EoB?= MXTJR|UxRTFyMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NIjzcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
UMPEL-1 NE\2XJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KwfVM6NTF{NUCgcm0> MknJOUBl MVTEUXNQyqB? MkjuTWM2OD1|MjDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NUXFcpAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
UMPEL-3 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjEN|kuOTJ3MDDuUS=> Mln4OUBl NH\mOHpFVVORwrC= MWDJR|UxRTFzMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BC-1 NVfFTppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorpN|kuOTJ3MDDuUS=> MWC1JIQ> MYLEUXNQyqB? MXfJR|UxRTd2NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BCP-1 M{Hlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmzPU0yOjVyIH7N NXfHVZFUPSCm MnvISG1UV8Li NIf4PYVKSzVyPUO5OkBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> MlK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
APK-1 NIrYfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Gxe|M6NTF{NUCgcm0> MV[1JIQ> M37Tb2ROW00EoB?= MXPJR|UxRTJ{NjDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NF6xN|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
RPMI8226  M1jSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HpUVAvODFvNUCg{txO NXvD[pU2PDhiaB?= MmTUSG1UV8Li M{XBWGlEPTB;ODFOwG0> MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUe4O|IoRjJ4MEm3PFczRC:jPh?=
OPM2  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP4NWIxNjBzLUWwJO69VQ>? M4WzVlQ5KGh? NX\YNpN3TE2VT9Mg M1;wfmlEPTB;MUCg{txO MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3Nkc,OjZyOUe4O|I9N2F-
RPMI8226  MmnvSpVv[3Srb36gRZN{[Xl? MoXkNVAh|ryP NFu0O|g1QCCq NF;SSFdFVVORwrC= M{XBcpN1emWwZ4To[Y5{KGO7dH;wcIF{dWmlLX71Z4xm[XJic3j1eJRtcW6pIH;mJI1VV1JiYX7kJJAudVSRUjDwdo91\Wmw M{\3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm3PFczLz5{NkC5O|g4OjxxYU6=
OPM2  NXnnc2JjTnWwY4Tpc44hSXO|YYm= NIrjRnkyOCEQvF2= MmWyOFghcA>? MkjVSG1UV8Li NEfnboh{fHKnbnf0bIVveyCleYTvdIxie22rYz3ueYNt\WG{IIPoeZR1dGmwZzDv[kBuXE:UIHHu[EBxNW2WT2KgdJJwfGWrbh?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3Nkc,OjZyOUe4O|I9N2F-
RPMI8226 MmL1SpVv[3Srb36gRZN{[Xl? M2TtdFAvOS1zMDFOwG0> MYC0JIg> NFnN[HVFVVORwrC= M3jrXolv[3KnYYPld{BXTUeIIH3SUmEh\XiycnXzd4lwdg>? NV21[mNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVM6QTBpPkK1NFU{QTlyPD;hQi=>
SH-SY5Y  Ml30RZBweHSxc3nzJGF{e2G7 Mln2NlXDqM7:Zz;tUC=> NWDqPFhZOcLiaB?= MVzjZZV{\XNic4TheIl{fGmlYXzsfUB{cWewaX\pZ4FvfCC{ZXT1Z5Rqd25iaX6gZo91cCCFUF[tJIFv\CCFUF[rR20ucW6mdXPl[EBieG:ydH;zbZPDqA>? M{Xrc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUe1Nlc3Lz5{NEm3OVI4PjxxYU6=
JJN3 NHXLfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TsZ|AvOS1zMECg{txO M4jXZlczKGh? MXPEUXNQ MXnpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> NEHNR3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
XG-1 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGx[YMyOC5zLUGwNEDPxE1? MYq3NkBp Mly3SG1UVw>? Ml;NbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NEXmZnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
CD138+  NIHaN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCwMlEuOTByIN88US=> MlfSO|IhcA>? NH\ZS4pFVVOR NW\GO3hEcW6qaXLpeJMh[2WubDDndo94fGh? M13yZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUe4N|c5Lz5{M{G3PFM4QDxxYU6=
XG-1 NFf4fIhHfW6ldHnvckBCe3OjeR?= MXiyM|ExOCEQvF2= M3jFNFI1KGh? MW\EUXNQ MXTpcohq[mm2czDDR2w{N02LUD2x{tEhdVKQQTDlfJBz\XO|aX;u NV3E[|BWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxO|g{PzhpPkKzNVc5Ozd6PD;hQi=>
U266 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HvbFAvODFvMUCg{txO NV;tepFbPDkkgJno M{\RSGROW09? NXHBNFBzcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3MkCwPEc,OjJ3NUKwNFg9N2F-
CRBN60 NVP0RoNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULNbm5VOC5yMT2xNEDPxE1? MmPpOFjjiImq M3\xdWROW09? MVrpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MlPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUKwNFgoRjJ{NUWyNFA5RC:jPh?=
CRNB75 M{fvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\NWZkxNjBzLUGwJO69VQ>? NEnGXXI1QOLCiXi= NILKfWlFVVOR MlXnbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3j1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWyNFA5Lz5{MkW1NlAxQDxxYU6=
MM.1S Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHQNE4xOS1zMDFOwG0> MofPOFjjiImq NFPwNYZFVVOR Mn7md4lodmmoaXPhcpRtgSCrbnjpZol1eyCycn;sbYZmemG2aX;uJIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzzszN M1fxe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
OPM2 NFzPbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj0WXY5OC5yMT2xNEDPxE1? NX;ifJdoPDkkgJno NGHwdndFVVOR MnfCd4lodmmoaXPhcpRtgSCrbnjpZol1eyCycn;sbYZmemG2aX;uJIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzzszN NH22U|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
MM.1S M2HRbmZ2dmO2aX;uJGF{e2G7 M3juOVExKM7:TR?= MWO3NkBp MmPkSG1UVw>? M{LOSpNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> M12wOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
H929 NHvJTVlHfW6ldHnvckBCe3OjeR?= M3PFR|ExKM7:TR?= M3zsWVczKGh? MUPEUXNQ M2PJU5Nq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> NVrLbotrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPFk{OjdpPkKxN|g6OzJ5PD;hQi=>
OPM2 MY\GeY5kfGmxbjDBd5NigQ>? M3K1c|ExKM7:TR?= MkP0O|IhcA>? NVTjW5VuTE2VTx?= MWLzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgdJJwfGWrbjDs[ZZmdCCxZjDDM2VDWM7{IHnzc4Zwem2|wrC= M1fKU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
CT26 NXf0bpd3TnWwY4Tpc44hSXO|YYm= M{faSVEwOTBizszN Mmr4NlQhcA>? MYHy[YR2[2W|IITo[UBvfW2kZYLzJI9nKGyrdnWgZ49td26rZYRCpC=> NHLkOoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zPFk4Pyd-MUm2N|g6Pzd:L3G+
T-cells NFHjWWpHfW6ldHnvckBie3OjeR?= NY\F[2k6OiC2bzCzJIRigXN? NV61V5JXUW6qaXLpeIlwdiCxZjDJUE0zKHC{b3T1Z5Rqd25iaX6gbJVu[W5iVDDj[YxteyCvZXHzeZJm\CCjZoTldkAzKHSxIEOg[IF6eyCkeTDFUGlUSSxiRVO1NEA:KDBwMEC4JO69VS5? MnzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNkiwNVkoRjJ|MU[4NFE6RC:jPh?=
DF15 M4LBc2Z2dmO2aX;uJIF{e2G7 MlvQOEBpenN? NEDXW21KdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB{MjFOwG0v NWrJUoJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 MlvVSpVv[3Srb36gZZN{[Xl? NHXYXFk1KGi{cx?= NVfJdndkUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHnrZZJweyCmZXfyZYRifGmxbjDpckBpfW2jbjDESlE2KGOnbHzzJIV5eHKnc4Ppcoch\VCOLYTh[4dm\CCra3Hyc5Mh[W[2ZYKgOEBpenNiYomgcJVucW6xbXX0dolkKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMkSg{txONg>? NU\Zfot6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 NUX4V2xlTnWwY4Tpc44h[XO|YYm= NUjnUXdUPCCqcoO= NHfKSmdKdmS3Y4Tpc44hd2ZiQ2LMOE9EWkKQIIXibZF2cXSrbjDsbYdie2VvbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BxVE:FLXXQUE11[WepZXSgZYlwdG:|IHHmeIVzKDRiaILzJIJ6KGy3bXnu[ZNk\W6lZTDiZZNm\CCkZYThMYdidGGldH;zbYRie2ViZX76fY1mKG[{YXft[Y51[XSrb36gZ49ueGynbXXueIF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5yMkeg{txONg>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3OEWwO{c,Ojh|NUi1NFc9N2F-
NAMALWA MmHURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWDoUWtkPzJiaILz MkLRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQV3BUHdCKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrbnPvdpBwemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwJF0hOC5yMzFOwG0v NHHUXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2PFAyQSd-MkOxOlgxOTl:L3G+
HeLa MmDDSpVv[3Srb36gZZN{[Xl? MUXJcohq[mm2aX;uJI9nKEmOLUGtZYxxcGFvaX7keYNm\CCQRj3rZZBx[UJiYXP0bZZifGmxbjDpckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHLsc4NscW6pIH;mJJA2OC:yNkWgcpVkdGWjcjD0doFve2yxY3H0bY9vNCCLQ{WwJF0hOS5{NzFOwG0v MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd6NEW4OVAoRjF5OES1PFUxRC:jPh?=
DF15 MV\GeY5kfGmxbjDhd5NigQ>? NWC1NlVNOC5yMTD0c{AyKHWP M3fqTlUhcHK| MoTXTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ Ml3hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
OPM2 M4W2[GZ2dmO2aX;uJIF{e2G7 MlzNNE4xOSC2bzCxJJVO NGWzfVY2KGi{cx?= MWPJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE:STUKgZ4VtdHNiYYSgNE4xOSC2bzCxJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> NFfr[3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
DF15 Mk\pSpVv[3Srb36gZZN{[Xl? NIO5XoExNjBzIITvJFEhfU1? NIK0dlk2KGi{cx?= NFr1R2pKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiaXvhdo9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5yMTD0c{AyKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NXHM[JFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 NXHzd4gyTnWwY4Tpc44h[XO|YYm= MWOwMlAyKHSxIEGgeW0> NV;VWIVvPSCqcoO= Mm\5TY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCRUF2yJINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ NEX1UFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
Assay
Methods Test Index PMID
Western blot CEBPβ ; IKZF1 / IKZF3 / UBE2G1 / CRBN 21389327 30234487
Immunofluorescence IKZF1 29496670
In vivo

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

Protocol (from reference)

Kinase Assay:

[1]

  • Inhibition of TNF-α synthesis:

    TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.

Cell Research:

[4]

  • Cell lines: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • Concentrations: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • Incubation Time: 24 or 48 hours
  • Method:

    For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.

Animal Research:

[4]

  • Animal Models: Disseminated lymphoma-bearing SCID mice
  • Dosages: 0.5 mg/kg
  • Administration: Injection i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

3mg/mL

Chemical Information

Molecular Weight 273.24
Formula

C13H11N3O4

CAS No. 19171-19-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04902443 Recruiting Drug: Pomalidomide|Drug: Nivolumab Viral Associated Malignancies|Kaposi Sarcoma|EBV/KSHV-associated Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 10 2021 Phase 1
NCT04577755 Recruiting Drug: Pomalidomide Skin Kaposi Sarcoma National Cancer Institute (NCI) July 1 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

Answer:
S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

Question 2:
I would like to know if the pomalidomide is racemic or optically active?

Answer:
Our S1567 Pomalidomide is racemic.

Tags: buy Pomalidomide (CC-4047) | Pomalidomide (CC-4047) supplier | purchase Pomalidomide (CC-4047) | Pomalidomide (CC-4047) cost | Pomalidomide (CC-4047) manufacturer | order Pomalidomide (CC-4047) | Pomalidomide (CC-4047) distributor